Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2): Research Guide

Adipotide is a synthetic chimeric peptide consisting of two functional domains connected by a glycine-glycine (GG) dipeptide linker. The N-terminal homing domain CKGGRAKDC is a cyclic peptide identified through in vivo phage display screening of the vasculature of white adipose tissue (WAT) in mice. The C-terminal effector domain D(KLAKLAK)2 is a synthetic amphipathic peptide composed entirely of D-amino acids designed to disrupt mitochondrial membranes upon cellular internalization. The complete sequence is CKGGRAKDC-GG-D(KLAKLAK)2.

The estimated molecular weight of Adipotide is approximately 2,520 Da depending on the cyclization state and counterion form. The N-terminal homing peptide contains two cysteine residues that form an intramolecular disulfide bond, creating a cyclic constraint necessary for high-affinity binding to the target receptor prohibitin. The C-terminal D(KLAKLAK)2 domain uses D-amino acids to confer protease resistance, ensuring that the pro-apoptotic payload remains intact during transit to the target endothelium and after internalization into endothelial cells.

The chimeric design of Adipotide represents a vascular-targeted approach to tissue remodeling. Rather than acting on adipocytes directly, the peptide selectively destroys the blood supply to adipose tissue, causing secondary adipocyte death through ischemia. This vascular targeting strategy was developed by Wadih Arap and Renata Pasqualini at the University of Texas MD Anderson Cancer Center, building on their extensive work with phage display-identified vascular homing peptides originally developed for targeted cancer therapy.

• Homing domain: CKGGRAKDC (cyclic, disulfide-bonded)
• Linker: GG (glycine-glycine spacer)
• Effector domain: D(KLAKLAK)2 (all D-amino acids)
• Molecular weight: ~2,520 Da
• Target receptor: Prohibitin (PHB) on adipose endothelium
• Mechanism: Vascular-targeted apoptosis
• Discovery: In vivo phage display (Arap/Pasqualini lab)
• Key feature: D-amino acid effector for protease resistance

The homing peptide CKGGRAKDC binds to prohibitin (PHB), a ~30 kDa protein that is normally located in the inner mitochondrial membrane where it functions as a chaperone in the assembly of respiratory chain complexes. However, proteomic and immunohistochemical studies revealed that prohibitin is also expressed on the luminal surface of endothelial cells in the vasculature of white adipose tissue, where it serves as a cell-surface receptor accessible to circulating ligands. This ectopic surface expression appears to be relatively specific to adipose vasculature in adult tissues.

The vascular homing specificity of CKGGRAKDC was established through systematic in vivo phage display biopanning. Phage libraries displaying random peptides were injected intravenously into mice, and phage that accumulated selectively in the vasculature of white adipose tissue depots were recovered and sequenced. CKGGRAKDC emerged as the dominant adipose-homing peptide motif. Subsequent validation using fluorescently labeled synthetic peptide confirmed selective accumulation in adipose tissue vasculature with minimal accumulation in other organ vascular beds.

Prohibitin as a vascular surface marker in adipose tissue has been validated across multiple species including mouse, rat, and non-human primate. The expression level correlates with the degree of adipose tissue vascularization, with highly vascularized visceral fat depots showing stronger prohibitin surface expression than subcutaneous depots. This differential expression may contribute to the preferential reduction of visceral adiposity observed in some Adipotide studies, though the visceral-to-subcutaneous specificity ratio varies across experimental systems.

Upon binding to surface prohibitin, the Adipotide-prohibitin complex is internalized via receptor-mediated endocytosis into the endothelial cell. Once in the cytoplasm, the D(KLAKLAK)2 effector domain localizes to mitochondria, driven by its amphipathic helical structure and positive charge that mimics mitochondrial targeting sequences. At the mitochondrial surface, D(KLAKLAK)2 disrupts the outer mitochondrial membrane through a mechanism analogous to antimicrobial peptide-mediated membrane permeabilization.

Mitochondrial membrane disruption by D(KLAKLAK)2 triggers the intrinsic apoptosis cascade: cytochrome c release, apoptosome formation, and caspase-9/caspase-3 activation. The use of D-amino acids in the effector domain is critical because L(KLAKLAK)2 is rapidly degraded by intracellular proteases before reaching mitochondria. The D-amino acid configuration renders the peptide invisible to cellular proteolytic machinery, allowing intact delivery to mitochondria. Studies with fluorescent Adipotide conjugates confirm mitochondrial co-localization within 2-4 hours of endothelial cell treatment.

The apoptosis of endothelial cells in the adipose vascular bed leads to local vessel regression, reducing blood supply to the surrounding adipocytes. Deprived of nutrients and oxygen, adipocytes undergo secondary necrosis and are cleared by tissue macrophages. This vascular-mediated tissue remodeling mechanism is fundamentally different from direct adipocyte targeting and produces a more complete ablation of adipose tissue within the affected vascular territory. Histological analysis shows vessel rarefaction, adipocyte shrinkage, and macrophage infiltration in treated adipose depots within 7-14 days.

Initial proof-of-concept studies in diet-induced obese (DIO) mice demonstrated that Adipotide treatment produced significant body weight reduction. Mice receiving daily subcutaneous injections of Adipotide (1-10 mg/kg) for 4 weeks showed dose-dependent weight loss, with high-dose groups losing approximately 30% of initial body weight. Fat mass measured by DEXA was reduced by over 50%, while lean mass was relatively preserved. The selective loss of fat mass over lean mass suggested targeted adipose tissue ablation rather than generalized catabolic effects.

Metabolic improvements accompanied the weight loss in rodent models. DIO mice treated with Adipotide showed improved glucose tolerance, reduced fasting insulin, decreased hepatic steatosis, and normalized circulating lipid profiles. Food intake was transiently reduced during the first week of treatment but normalized thereafter, and the continued weight loss beyond the initial anorectic period was attributed to the direct vascular-targeted mechanism. Pair-feeding control experiments confirmed that weight loss exceeded what could be explained by reduced food intake alone.

Histological examination of adipose tissue from Adipotide-treated mice revealed extensive vascular regression, adipocyte death, and macrophage-mediated clearance of tissue debris. Brown adipose tissue (BAT) was relatively spared, consistent with the lower prohibitin surface expression on BAT vasculature. The preservation of BAT thermogenic capacity may contribute to the maintenance of energy expenditure during Adipotide-induced weight loss, preventing the compensatory metabolic slowdown observed with caloric restriction.

The most significant Adipotide preclinical data came from a study in spontaneously obese rhesus monkeys (Macaca mulatta) conducted at the MD Anderson Cancer Center. Obese male rhesus monkeys (BMI >40) received daily subcutaneous Adipotide injections for 28 days. Treatment produced an average body weight reduction of 11% and a 38% reduction in abdominal fat as measured by MRI. Body mass index decreased significantly, and the weight loss was maintained during a follow-up period after treatment cessation.

Metabolic parameters improved substantially in the primate study. Insulin sensitivity measured by hyperinsulinemic-euglycemic clamp improved by approximately 50%. Fasting glucose and insulin levels decreased, and circulating adiponectin (an insulin-sensitizing adipokine) increased. The metabolic improvements correlated with the degree of visceral fat loss, suggesting that preferential reduction of metabolically active visceral adipose tissue drove the systemic metabolic benefits. MRI body composition analysis confirmed that visceral fat depots were reduced proportionally more than subcutaneous depots.

The primate study provided the most translationally relevant efficacy data for Adipotide, as rhesus monkeys share considerable physiological similarity with humans in adipose tissue distribution, vascular biology, and metabolic regulation. The magnitude of weight loss and metabolic improvement in a spontaneously obese primate model exceeded what had been achieved with most pharmaceutical interventions at that time and generated substantial scientific and media attention.

The most significant safety finding in Adipotide preclinical studies was renal toxicity. In the rhesus monkey study, treated animals developed elevated serum creatinine and BUN (blood urea nitrogen), indicating reduced renal function. Urinalysis revealed proteinuria and the presence of renal tubular cells, suggesting direct kidney injury. Histological examination showed proximal tubular necrosis with evidence of peptide accumulation in renal tubular epithelium. The renal effects were dose-dependent and partially reversible after treatment cessation.

The mechanism of Adipotide nephrotoxicity likely involves two components: (1) non-specific uptake of the peptide by the proximal tubular epithelium during renal filtration and reabsorption, exposing tubular cells to the D(KLAKLAK)2 pro-apoptotic domain; and (2) potential prohibitin expression on renal vascular endothelium creating on-target toxicity in the kidney. The kidney is particularly vulnerable because the proximal tubule actively reabsorbs filtered peptides via megalin/cubilin receptor-mediated endocytosis, concentrating Adipotide in tubular cells.

The renal findings represent the primary challenge for Adipotide development. Strategies proposed to mitigate nephrotoxicity include dose optimization, intermittent dosing schedules, PEGylation to increase molecular size above the renal filtration threshold, and engineering of second-generation homing peptides with improved selectivity for adipose over renal vasculature. These modifications remain in the preclinical research stage, and no clinical trials of Adipotide in humans have been reported.

Adipotide produces a distinctive body composition change characterized by preferential fat mass loss with relative lean mass preservation. In both rodent and primate studies, DEXA and MRI analyses confirmed that the body weight reduction was predominantly attributable to reduced adiposity rather than loss of muscle, bone, or organ mass. This favorable body composition effect distinguishes Adipotide from caloric restriction, which typically produces proportional losses of both fat and lean tissue.

The metabolic consequences of Adipotide-induced fat loss extend beyond simple weight reduction. Decreased adipose tissue mass reduces the secretion of pro-inflammatory adipokines (TNF-alpha, IL-6, resistin, MCP-1) while increasing circulating adiponectin. The improved adipokine profile contributes to resolution of the chronic low-grade inflammation associated with obesity and restoration of insulin signaling in peripheral tissues. Additionally, the reduction in ectopic lipid deposition (hepatic and intramuscular) relieves lipotoxic stress on non-adipose tissues.

Analytical characterization of Adipotide requires methods capable of assessing both the linear and cyclic structural elements. RP-HPLC with UV detection at 220 nm provides purity assessment, with research-grade material typically specified at greater than 95% purity. The intramolecular disulfide bond status is critical for biological activity and can be verified by comparing retention times under reducing (DTT/TCEP) and non-reducing conditions, or by Ellman reagent assay for free thiol quantification.

Mass spectrometric analysis by MALDI-TOF or ESI-MS confirms molecular identity. The presence of D-amino acids in the effector domain cannot be distinguished from L-amino acids by mass spectrometry alone; chiral analysis by Marfey reagent derivatization followed by RP-HPLC or by chiral amino acid analysis after acid hydrolysis is required to confirm the D-configuration. For in vivo studies, quantification of Adipotide in plasma and tissue extracts employs LC-MS/MS with selected reaction monitoring (SRM) transitions specific to the unique peptide sequence.

The following publications represent the primary research literature on Adipotide and vascular-targeted approaches to adipose tissue remodeling.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism